A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Phase

Condition

Amyloidosis

Treatment

ALN-TTRSC04

Placebo

Clinical Study ID

NCT05661916

ALN-TTRSC04-001

Ages 18-65
All Genders
Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Body mass index (BMI) ≥18.0 kg/m^2 and ≤30 kg/m^2 assessed at Screening.

Exclusion

Exclusion Criteria:

Has an estimated glomerular filtration rate (eGFR) <90 mL/min/1.73m^2 at screening.
Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or directbilirubin above the upper limit of normal (ULN).

Study Design